Praxis Precision Medicines
PRAX
86 hedge funds and large institutions have $43.1M invested in Praxis Precision Medicines in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 39 increasing their positions, 19 reducing their positions, and 29 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 19
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0.35% more ownership
Funds ownership: 6.43% → 6.77% (+0.35%)
17% less funds holding
Funds holding: 103 → 86 (-17)
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
60% less capital invested
Capital invested by funds: $108M → $43.1M (-$64.7M)
92% less call options, than puts
Call options by funds: $17K | Put options by funds: $204K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$14.6M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$12M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$7.07M |
| 4 |
TLP
Tri Locum Partners
New York
|
+$6.93M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Blackstone Inc
New York
|
-$10.8M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$8.37M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.77M |
| 4 |
AG
Artal Group
Luxembourg
|
-$2.86M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$1.9M |
PRAX Hedge Fund Activity: Q1 2023 in Review
86 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2023, worth a combined $43.1M — down 60% from $108M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of PRAX and 12 opened new positions — a net loss of 17 holders — while 19 trimmed existing stakes and 39 added.
The largest buyer was Velan Capital Investment Management, opening a new position worth an estimated $14.6M. The largest seller was Blackstone Inc, cutting an estimated $10.8M.
- 86 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2023, down from 103 in Q4 2022.
- Funds reported $43.1M of Praxis Precision Medicines stock for Q1 2023, down 60% quarter-over-quarter.
- 12 funds opened new Praxis Precision Medicines positions in Q1 2023 and 29 closed out, a net change of -17 holders.
- The largest Praxis Precision Medicines buyer in Q1 2023 was Velan Capital Investment Management, an estimated $14.6M added.
- The largest Praxis Precision Medicines seller in Q1 2023 was Blackstone Inc, an estimated $10.8M sold.
Based on aggregated 13F filings for Q1 2023.